Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Snake River Research PLLC

Neither a doctor nor a teaching hospital

Research payments

$1,433,735

546 payments

Through program year 2025, Snake River Research PLLC is reported as receiving $1,433,735 in research payments, across 546 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $210,377 92
2024 Research $72,110 10
2023 Research $222,481 23
2022 Research $201,252 181
2021 Research $279,233 112
2020 Research $270,752 69
2019 Research $177,531 59

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $1,108,702 457 payments
  2. Novartis Pharmaceuticals Corporation $161,812 2 payments
  3. Becton, Dickinson and Company $69,615 1 payment
  4. Moderna TX, Inc. $62,932 74 payments
  5. GlaxoSmithKline, LLC. $30,674 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $631,490 56 payments
  2. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $190,213 315 payments
  3. A Phase 3 Randomized Observerblinded Study to Evaluate the Immunogenicity Safety and Tolerability of 2 Doses Compared to 3 Doses of Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $173,193 35 payments
  4. Phase 3 Randomised, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With Covid-19 Associated Cytokine Storm (Ruxcovid) $101,080 1 payment
  5. SARS CoV-2 $69,615 1 payment
  6. A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults $62,932 74 payments
  7. A Phase 2, Randomized, Placebo-Controlled, Participant and Investigator Blinded, Multi-Center Study to Assess Efficacy and Safety of Mas825 for the Treatment of Sars-Cov-2 Infected Patients With Covid-19 Pneumonia and Impaired Respiratory Function $60,732 1 payment
  8. A Phase 2 Placebocontrolled Randomized Proof of Concept Study of A Respiratory Syncytial Virus RSV Vaccine in Pregnant Women $30,413 11 payments
  9. A Phase 2B Doubleblind Randomized Placebocontrolled Parallel Group Dose Ranging Study to Evaluate Virological Response and Safety of Oral Pf07817883 in Nonhospitalized Symptomatic Adult Participants With Covid19 $29,142 6 payments
  10. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $27,854 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record